Table 1

Six patients with antineutrophil cytoplasm antibodies-associated vasculitis contracted COVID-19

PatientAgeSexInduction therapyMaintenance therapyImmunsuppression (within the last 6 months)Admission to hospitalSerum creatinine (mg/dL) before COVID-19HypogammaglobulinaemiaCOVID-19 renal outcomeCOVID-19 overall outcomeSerum creatinine (mg/dL) after COVID-19SARS-CoV-2 antibodies
172MYesCyclophosphamide 3.09 g (3 pulses), rituximab (2×1 g), methylprednisolone (3.06 g)Yes3.30Moderate (IgG 336 mg/dL)AKI (peak creatinine 5.12)Oxygen supply (max. 4 L), steroids increased2.45Detectable
262MYesRituximab (1 g)Yes1.19Moderate (IgG 409 mg/dL)AKI (peak creatinine 1.73)Non-invasive ventilation, remdesivir, dexamethasone, convalescent plasma1.38Not detectable
361MNo1.35No (IgG 1150 mg/dL)Home quarantine1.29
480FNo3.06No (IgG 1100 mg/dL)Home quarantine2.33Detectable
556FNo0.86No (IgG 705 mg/dL)Home quarantine0.84Detectable
639FYesRituximab (1 g)No0.75No (IgG 1120 mg/dL)Home quarantine0.75not detectable
  • AKI, acute kidney injury; F, female; M, male.